EBR 4.47% 85.5¢ ebr systems inc.

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-4

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 4,746 Posts.
    lightbulb Created with Sketch. 1872
    Seems to me a couple of anonymous posters don't have enough shares, and hope their negative remarks will enable them to buy shares a little cheaper.
    IMO there is no need for another CR any time soon, holding A$98 million cash, and commercialisation targeted for Q1 2025.

    Everything appears on track for FDA submission Q3 2024:
    "Regulatory and commercial readiness activities progressing to schedule, with EBR on track to submit the final module of its Pre-Market Approval (“PMA”) Application to the U.S. Food and Drug Administration (“FDA”) in Q3 2024. The Company is targeting FDA approval in Q1 2025".

    and

    "EBR continues to progress its regulatory and commercialisation agenda, building on the positive SOLVE-CRT trial results announced in the prior year."

    and

    "John McCutcheon, EBR Systems’ President & Chief Executive Officer said: “We have made positive strides in our regulatory and commercialisation agenda, pushing us closer towards our final PMA submission in Q3 2024.....Our final regulatory and testing procedures remain on track, underpinning our confidence in achieving our Q3 2024 submission target. We remain highly focused on positioning EBR for success post-regulatory approval and ensuring WiSE® CRT realises the commercial potential in which we firmly believe."
 
watchlist Created with Sketch. Add EBR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.